Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study.
Sherko KuemmelCarlo A TondiniJacinta AbrahamZbigniew NoweckiBartosz ItrychErika HitreBogusława KaraszewskaAlejandro Juárez-RamiroFlavia Morales-VásquezJose Manuel Pérez-GarcíaServando Cardona-HuertaEstefania MonturusMarco SequiEleonora RestucciaMark BenyunesMiguel MartínPublished in: Breast cancer research and treatment (2021)
NCT02402712.